Preoperative single-bolus high-dose antithymocyte globulin as induction therapy in sensitized renal transplant recipients

Chinese Medical Journal

Volumn 119, Issue 20, 2006, Pages 1683-1688

  Wang, Dong ^a   Wu, Wei Zhen ^a   Yang, Shun Liang ^a   Chen, Jin Hua ^a   Tan, Jian Ming ^a  

^a FUZHOU GENERAL HOSPITAL   (China)

Author keywords

Antilymphocyte serum; Graft rejection; Immunization; Kidney transplantation

Indexed keywords

CYCLOSPORIN A; HEMOGLOBIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; THYMOCYTE ANTIBODY; TSUKUBAENOLIDE;

ACUTE GRAFT REJECTION; ADULT; ANEMIA; ARTICLE; BLOOD TOXICITY; BOLUS INJECTION; CHI SQUARE TEST; CONTROLLED STUDY; DONOR; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FOLLOW UP; GRAFT INFECTION; GRAFT RECIPIENT; GRAFT SURVIVAL; HOSPITALIZATION; HUMAN; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE TREATMENT; STUDENT T TEST; SURVIVAL RATE; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 33750740089     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200610020-00003     Document Type: Article

References (23)

1. Matas AJ, Ramcharan T, Paraskevas S, Gillingham KJ, Dunn DL, Gruessner RW, et al. Rapid discontinuation of steroids in-living donor kidney transplantation: a pilot study. Am J Transplant 2001; 1: 278-283.
2. Tejani A, Emmett L. Acute and chronic rejection. Semin Nephro 2001; 21: 498-507.
3. Thibaudin D, Alamartine E, de Filippis JP, Diab N, Laurent B, Berthoux F. Advantage of antithymocyte globulin induction in sensitized kidney recipients: a randomized prospective study comparing induction with and without antithymocyte globulin. Nephrol Dial Transplant 1998; 13: 711-715.
4. Ault BH, Honaker MR, Osama Gaber A, Jones DP, Duhart Jr BT, Powell SL, et al. Short-term outcomes of Thymoglobulin induction in pediatric renal transplant recipients. Pediatr Nephrol 2002; 17: 815-818.
5. Abou J, Almawi W. Intraoperative anti-thymocyte globulin-Fresenius (ATG-F) administration as induction immunosuppressive therapy in kidney transplantation. Mol Immunol 2003; 39: 1089-1094.
6. Opelz G. Collaborative transplant study - 10-year report. Transplant Proc 1992; 24: 2342-2345.
7. Gjertson D. A multi-factor analysis of kidney regraft outcomes. Clin Transpl 2002; 335-349.
8. Calne R. Prope tolerance: a step in the search for tolerance in the clinic. World J Surg 2000; 24: 793-796.
9. Almond PS, Matas A, Gillingham K, Dunn DL, Payne WD, Gores P, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55: 756-757.
10. First M. An update on new immunosuppressive drugs undergoing pre-clinical and clinical trials: potential applications in organ transplantation. Am J Kidney Dis 1997; 29: 303-317.
11. Agha IA, Rueda J, Alvarez A, Singer GG, Miller BW, Flavin K, et al. Short course induction immunosuppression with thymoglobulin for renal transplant recipients. Transplantation 2002; 73: 473-475.
12. Toronyi E, Remport A, Jaray J, Mathe Z, Borka P, Perner F. Evaluation of various immunosuppressive regimes in second renal transplants. Transplant Proc 2001; 33: 2315-2316.
13. Szczech LA, Berlin JA, Aradhye S, Grossman RA, Feldman HI. Effect of anti-lymphocyte induction therapy on renal allograft survival: a meta-analysis. J Am Soc Nephrol 1997; 8: 1771-1777.
14. Lange H, Muller TF, Ebel H, Kuhlmann U, Grebe SO, Heymanns J, et al. Immediate and long-term results of ATG induction therapy for delayed graft function compared to conventional therapy for immediate graft function. Transplant Int 1999; 12: 2-9.
15. Meier-Kriesche HU, Arndorfer JA, Kaplan B. Association of antibody induction with short- and long-term cause-specific mortality in renal transplant recipients. J Am Soc Nephrol 2002; 13: 769-772.
16. Ducloux D, Kazory A, Challier B, Coutet J, Bresson-Vautrin C, Motte G, et al. Long-term toxicity of antithymocyte globulin induction may vary with choice of agent: a single-center retrospective study. Transplantation 2004; 77: 1029-1033.
17. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4: 222-230.
18. Kaden J, May G, Strobelt V, Groth J, Muller P. Intraoperative T-cell depletion prior to completion of anastomoses by high-dose single ATG bolus as a new approach to improve long-term results after kidney transplantation. Transplant Proc 1997; 29:344-347.
19. Yussim A, Shapira Z. Single-bolus high-dose ATG for prophylaxis of rejection in renal transplantation - a prospective, randomized study. Transplant Int 2000; 13 Suppl 1: s293-s294.
20. Abudher MN, Moorhead JF, Fernando ON, Varghese Z. Preoperative ATG bolus treatment increase CsA sensitivity of peripheral blood lymphocytes (PBLS) in renal transplant patients. Transplant Proc 1999; 31: 3361-3364.
21. Nampoory MR, Abdulhalim M, Johny KV, Al-Jawad Donia FA, Nair MP, Said T, et al. Bolus anti-thymocyte globulin induction in renal transplant recipients: a comparison with conventional ATG or anti-interleukin-2 receptor antibody induction. Transplant Proc 2002; 34: 2916-2919.
22. Goggins WC, Pascual MA, Powelson JA, Magee C, Tolkoff-Rubin N, Farrell ML, et al. A prospective, randomized, clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal transplant recipients. Transplantation 2003; 76: 798-802.
23. Yang S, Tian J, Wu W. Prevention of rejection by Simulect in sensitized kidney allograft recipients. Chin J Organ Transplant (Chin) 2004; 25: 157-159.